Literature DB >> 20726553

A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

Andrew X Zhang1, Ryan P Murelli, Cyril Barinka, Julien Michel, Alexandra Cocleaza, William L Jorgensen, Jacek Lubkowski, David A Spiegel.   

Abstract

Prostate specific membrane antigen (PSMA) is a membrane-bound glutamate carboxypeptidase overexpressed in many forms of prostate cancer. Our laboratory has recently disclosed a class of small molecules, called ARM-Ps (antibody-recruiting molecule targeting prostate cancer) that are capable of enhancing antibody-mediated immune recognition of prostate cancer cells. Interestingly, during the course of these studies, we found ARM-Ps to exhibit extraordinarily high potencies toward PSMA, compared to previously reported inhibitors. Here, we report in-depth biochemical, crystallographic, and computational investigations which elucidate the origin of the observed affinity enhancement. These studies reveal a previously unreported arene-binding site on PSMA, which we believe participates in an aromatic stacking interaction with ARMs. Although this site is composed of only a few amino acid residues, it drastically enhances small molecule binding affinity. These results provide critical insights into the design of PSMA-targeted small molecules for prostate cancer diagnosis and treatment; more broadly, the presence of similar arene-binding sites throughout the proteome could prove widely enabling in the optimization of small molecule-protein interactions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20726553      PMCID: PMC2965167          DOI: 10.1021/ja104591m

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  59 in total

1.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

2.  PDDG/PM3 and PDDG/MNDO: improved semiempirical methods.

Authors:  Matthew P Repasky; Jayaraman Chandrasekhar; William L Jorgensen
Journal:  J Comput Chem       Date:  2002-12       Impact factor: 3.376

3.  Using bifunctional polymers presenting vancomycin and fluorescein groups to direct anti-fluorescein antibodies to self-assembled monolayers presenting d-alanine-d-alanine groups.

Authors:  Steven J Metallo; Ravi S Kane; R Erik Holmlin; George M Whitesides
Journal:  J Am Chem Soc       Date:  2003-04-16       Impact factor: 15.419

4.  Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase).

Authors:  A P Kozikowski; F Nan; P Conti; J Zhang; E Ramadan; T Bzdega; B Wroblewska; J H Neale; S Pshenichkin; J T Wroblewski
Journal:  J Med Chem       Date:  2001-02-01       Impact factor: 7.446

5.  Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.

Authors:  B S Slusher; J J Vornov; A G Thomas; P D Hurn; I Harukuni; A Bhardwaj; R J Traystman; M B Robinson; P Britton; X C Lu; F C Tortella; K M Wozniak; M Yudkoff; B M Potter; P F Jackson
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

6.  Cation-pi interactions in structural biology.

Authors:  J P Gallivan; D A Dougherty
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

7.  Bacteria targeted by human natural antibodies using alpha-Gal conjugated receptor-specific glycopolymers.

Authors:  J Li; S Zacharek; X Chen; J Wang; W Zhang; A Janczuk; P G Wang
Journal:  Bioorg Med Chem       Date:  1999-08       Impact factor: 3.641

8.  Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors.

Authors:  Yingjuan Lu; Philip S Low
Journal:  Cancer Immunol Immunother       Date:  2002-03-19       Impact factor: 6.968

9.  Design and pharmacological activity of phosphinic acid based NAALADase inhibitors.

Authors:  P F Jackson; K L Tays; K M Maclin; Y S Ko; W Li; D Vitharana; T Tsukamoto; D Stoermer; X C Lu; K Wozniak; B S Slusher
Journal:  J Med Chem       Date:  2001-11-22       Impact factor: 7.446

10.  Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor.

Authors:  Pavel Majer; Paul F Jackson; Greg Delahanty; Brian S Grella; Yao-Sen Ko; Weixing Li; Qun Liu; Keith M Maclin; Jana Poláková; Kathryn A Shaffer; Doris Stoermer; Dilrukshi Vitharana; Eric Yanjun Wang; Anthony Zakrzewski; Camilo Rojas; Barbara S Slusher; Krystyna M Wozniak; Eric Burak; Tharin Limsakun; Takashi Tsukamoto
Journal:  J Med Chem       Date:  2003-05-08       Impact factor: 7.446

View more
  52 in total

1.  Grand challenge commentary: Synthetic immunology to engineer human immunity.

Authors:  David A Spiegel
Journal:  Nat Chem Biol       Date:  2010-12       Impact factor: 15.040

2.  Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2011-10-04       Impact factor: 2.823

3.  Bispecific small molecule-antibody conjugate targeting prostate cancer.

Authors:  Chan Hyuk Kim; Jun Y Axup; Brian R Lawson; Hwayoung Yun; Virginie Tardif; Sei Hyun Choi; Quan Zhou; Anna Dubrovska; Sandra L Biroc; Robin Marsden; Jason Pinstaff; Vaughn V Smider; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

4.  Prevalence and gene characteristics of antibodies with cofactor-induced HIV-1 specificity.

Authors:  Maxime Lecerf; Tobias Scheel; Anastas D Pashov; Annaelle Jarossay; Delphine Ohayon; Cyril Planchais; Stephane Mesnage; Claudia Berek; Srinivas V Kaveri; Sébastien Lacroix-Desmazes; Jordan D Dimitrov
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

Review 5.  Multivalent Antibody-Recruiting Macromolecules: Linking Increased Binding Affinity with Enhanced Innate Immune Killing.

Authors:  Annemiek Uvyn; Bruno G De Geest
Journal:  Chembiochem       Date:  2020-07-10       Impact factor: 3.164

Review 6.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

7.  Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.

Authors:  Sangeeta Ray Banerjee; Zhengping Chen; Mrudula Pullambhatla; Ala Lisok; Jian Chen; Ronnie C Mease; Martin G Pomper
Journal:  Bioconjug Chem       Date:  2016-05-09       Impact factor: 4.774

8.  The Small Molecule Hyperphyllin Enhances Leaf Formation Rate and Mimics Shoot Meristem Integrity Defects Associated with AMP1 Deficiency.

Authors:  Olena Poretska; Saiqi Yang; Delphine Pitorre; Wilfried Rozhon; Karin Zwerger; Marcos Castellanos Uribe; Sean May; Peter McCourt; Brigitte Poppenberger; Tobias Sieberer
Journal:  Plant Physiol       Date:  2016-05-03       Impact factor: 8.340

9.  Synthetic α-Hydroxytropolones as Inhibitors of HIV Reverse Transcriptase Ribonuclease H Activity.

Authors:  Ryan P Murelli; Michael P D'Erasmo; Danielle R Hirsch; Christine Meck; Takashi Masaoka; Jennifer A Wilson; Baofeng Zhang; Rajat K Pal; Emilio Gallicchio; John A Beutler; Stuart F J Le Grice
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

10.  Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer.

Authors:  Zhiwei Zhang; Zheng Zhu; Deyong Yang; Weiwei Fan; Jianbo Wang; Xiancheng Li; Xiaochi Chen; Qifeng Wang; Xishuang Song
Journal:  Oncol Lett       Date:  2016-06-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.